Posted by jrbecker on September 13, 2004, at 15:34:15
In reply to Re: List of Drugs in Development [updated], posted by incessant void on September 11, 2004, at 21:26:13
DOV just signed a big deal with Merck on the triple reuptake molecules. It's my guess that Merck is deciding which molecule (DOV 216,303 in Phase IIb; or DOV 21,947, starting up Phase II) to proceed with.
I believe that DOV was going to make some sort of announcement about one of DOV216,303's phase II results in 4Q. But we won't know for at least a few months if Merck will continue into phase III with 216,303 or will wait to see more trials on 21,947 first.
http://biz.yahoo.com/prnews/040805/nyth135_1.html
http://www.dovpharm.com/sub_page/product_dov216303.html
you will need the free microsoft powerpoint viewer software to see these slides...see "2nd Annual Science Day Presentations"
http://www.b2i.us/Profiles/Investor/Presentation.asp?BzID=590&sm_quote_field=DOVP&CName=DOV+Pharmaceutical%2C+Inc%2E
> that's a great chart, thank you so much!
>
> i'm interested in "DOV216,303" -- clicked on the link you had and the site said:
>
> " recently completed a dose-escalating, placebo-controlled, double-blind Phase I clinical trial in France that evaluated the blood levels and side effect profile produced by single doses of DOV 216,303. DOV 216,303 was rapidly absorbed following oral administration, with blood levels proportional to the administered dose. No adverse effects were observed after doses five to ten times higher than the projected therapeutic doses. We initiated a Phase Ib multiple dose-ranging clinical trial of DOV 216,303 in April 2002."
>
> do you have any more info? shouldn't this drug be further along than stage II? :(
>
poster:jrbecker
thread:389153
URL: http://www.dr-bob.org/babble/20040909/msgs/390357.html